Skip to main content
Erschienen in: Clinical Rheumatology 8/2018

20.04.2018 | Original Article

Late restoration of renal function in patients with severe ANCA-associated glomerulonephritis who were dialysis-dependent at presentation

verfasst von: Tian-Tian Ma, Yi-Ran Liu, Min Chen, Ming-Hui Zhao

Erschienen in: Clinical Rheumatology | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

In antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), many patients with severe renal dysfunction are on dialysis at presentation. Among those who got rid of dialysis finally, renal restoration happened mostly within the first 3 months of treatment. However, in clinical practice, we occasionally encountered patients who got rid of dialysis after 3 months. The current study investigated clinical and pathological features of AAV patients with so-called delayed renal function restoration. A total of 156 patients with ANCA-associated glomerulonephritis who were on dialysis at presentation were retrospectively recruited. Clinical and pathological data as well as treatment and outcomes were analyzed. Among these 156 patients, 58 and 12 patients got rid of dialysis within and after 3 months, respectively. Among the 12 patients with delayed renal function restoration, 8 and 4 patients got rid of dialysis within and after 6 months, respectively. Among the 72 patients who were still on dialysis at the end of 3 months since the initiation of immunosuppressive therapy, those receiving intravenous cyclophosphamide therapy over 3 months had significantly higher proportion of renal function restoration than those receiving intravenous cyclophosphamide for only 3 months (8/14 versus 4/58, P < 0.001). For patients with ANCA-associated glomerulonephritis who were on dialysis at presentation, there is an unnegligible proportion of patients who had their renal function restoration beyond 3 months since the initiation of immunosuppressive therapy. Further studies are needed to investigate whether, and for whom, cyclophosphamide prescription should be prolonged for more than 3 months.
Literatur
1.
Zurück zum Zitat Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitis. Arthritis Rheum 65(1):1–11CrossRefPubMed Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitis. Arthritis Rheum 65(1):1–11CrossRefPubMed
2.
Zurück zum Zitat Chaigne B, Guillevin L (2017) Vasculitis for the internist: focus on ANCA-associated vasculitis. Intern Emerg Med 12(5):577–585CrossRefPubMed Chaigne B, Guillevin L (2017) Vasculitis for the internist: focus on ANCA-associated vasculitis. Intern Emerg Med 12(5):577–585CrossRefPubMed
3.
Zurück zum Zitat Flores-Suárez LF, Alba MA, Mateos-Toledo H, Ruiz N (2017) Pulmonary involvement in systemic vasculitis. Curr Rheumatol Rep 19(9):56CrossRefPubMed Flores-Suárez LF, Alba MA, Mateos-Toledo H, Ruiz N (2017) Pulmonary involvement in systemic vasculitis. Curr Rheumatol Rep 19(9):56CrossRefPubMed
4.
Zurück zum Zitat Marzano AV, Raimondo MG, Berti E, Meroni PL, Ingegnoli F (2017) Cutaneous manifestations of ANCA-associated small vessels vasculitis. Clin Rev Allergy Immunol 53(3):428–438CrossRefPubMed Marzano AV, Raimondo MG, Berti E, Meroni PL, Ingegnoli F (2017) Cutaneous manifestations of ANCA-associated small vessels vasculitis. Clin Rev Allergy Immunol 53(3):428–438CrossRefPubMed
5.
Zurück zum Zitat Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C, European Vasculitis Study Group (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349(1):36–44CrossRefPubMed Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C, European Vasculitis Study Group (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349(1):36–44CrossRefPubMed
6.
Zurück zum Zitat Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, Plaisance M, Pusey CD, Jayne DR, Pan-Thames Renal Research Group (2003) Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 41(4):776–784CrossRefPubMed Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, Plaisance M, Pusey CD, Jayne DR, Pan-Thames Renal Research Group (2003) Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 41(4):776–784CrossRefPubMed
7.
Zurück zum Zitat Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage CO, Sinico RA, Stegeman CA, Westman KW, van der Woude FJ, de Lind van Wijngaarden RA, Pusey CD, European Vasculitis Study Group (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18(7):2180–2188CrossRefPubMed Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage CO, Sinico RA, Stegeman CA, Westman KW, van der Woude FJ, de Lind van Wijngaarden RA, Pusey CD, European Vasculitis Study Group (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18(7):2180–2188CrossRefPubMed
8.
Zurück zum Zitat Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group (2012) KDIGO clinical practice guideline for glomerulonephritis. Kidney Inter Suppl 2:139–274CrossRef Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group (2012) KDIGO clinical practice guideline for glomerulonephritis. Kidney Inter Suppl 2:139–274CrossRef
9.
Zurück zum Zitat Kidney disease: improving global outcomes (KDIGO) Acute Kidney Injury Work Group (2012) KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2:1–138CrossRef Kidney disease: improving global outcomes (KDIGO) Acute Kidney Injury Work Group (2012) KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2:1–138CrossRef
10.
Zurück zum Zitat Wang F, Hong D, Wang Y, Feng Y, Wang L, Yang L, ISN AKF 0 by 25 China Consortium (2017) Renal replacement therapy in acute kidney injury from a Chinese cross-sectional study: patient, clinical, socioeconomic and health service predictors of treatment. BMC Nephrol 18(1):152CrossRefPubMedPubMedCentral Wang F, Hong D, Wang Y, Feng Y, Wang L, Yang L, ISN AKF 0 by 25 China Consortium (2017) Renal replacement therapy in acute kidney injury from a Chinese cross-sectional study: patient, clinical, socioeconomic and health service predictors of treatment. BMC Nephrol 18(1):152CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Cruz DN, Ricci Z, Bagshaw SM, Piccinni P, Gibney N, Ronco C (2010) Renal replacement therapy in adult critically ill patients: when to begin and when to stop. Contrib Nephrol 165:263–273CrossRefPubMed Cruz DN, Ricci Z, Bagshaw SM, Piccinni P, Gibney N, Ronco C (2010) Renal replacement therapy in adult critically ill patients: when to begin and when to stop. Contrib Nephrol 165:263–273CrossRefPubMed
12.
Zurück zum Zitat Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W, Wang M, Xu GB, Wang HY (2006) Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 17(10):2937–2944CrossRefPubMed Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W, Wang M, Xu GB, Wang HY (2006) Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 17(10):2937–2944CrossRefPubMed
13.
Zurück zum Zitat Abril A, Calamia KT, Cohen MD (2003) The Churg Strauss syndrome (allergic granulomatous angiitis): review and update. Semin Arthritis Rheum 33(2):106–114CrossRefPubMed Abril A, Calamia KT, Cohen MD (2003) The Churg Strauss syndrome (allergic granulomatous angiitis): review and update. Semin Arthritis Rheum 33(2):106–114CrossRefPubMed
14.
Zurück zum Zitat Bajema IM, Hagen EC, Hansen BE, Hermans J, Noël LH, Waldherr R, Ferrario F, van der Woude FJ, Bruijn JA (1996) The renal histopathology in systemic vasculitis: an international survey study of inter- and intra-observer agreement. Nephrol Dial Transplant 11(10):1989–1995CrossRefPubMed Bajema IM, Hagen EC, Hansen BE, Hermans J, Noël LH, Waldherr R, Ferrario F, van der Woude FJ, Bruijn JA (1996) The renal histopathology in systemic vasculitis: an international survey study of inter- and intra-observer agreement. Nephrol Dial Transplant 11(10):1989–1995CrossRefPubMed
15.
Zurück zum Zitat Bajema IM, Hagen EC, Hermans J, Noël LH, Waldherr R, Ferrario F, Van Der Woude FJ, Bruijn JA (1999) Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Kidney Int 56(5):1751–1758CrossRefPubMed Bajema IM, Hagen EC, Hermans J, Noël LH, Waldherr R, Ferrario F, Van Der Woude FJ, Bruijn JA (1999) Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Kidney Int 56(5):1751–1758CrossRefPubMed
16.
Zurück zum Zitat Hauer HA, Bajema IM, van Houwelingen HC, Ferrario F, Noël LH, Waldherr R, Jayne DR, Rasmussen N, Bruijn JA, Hagen EC, European Vasculitis Study Group (EUVAS) (2002) Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int 61(1):80–89CrossRefPubMed Hauer HA, Bajema IM, van Houwelingen HC, Ferrario F, Noël LH, Waldherr R, Jayne DR, Rasmussen N, Bruijn JA, Hagen EC, European Vasculitis Study Group (EUVAS) (2002) Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int 61(1):80–89CrossRefPubMed
17.
Zurück zum Zitat Jennette JC (2003) Rapidly progressive crescentic glomerulonephritis. Kidney Int 63(3):1164–1177CrossRefPubMed Jennette JC (2003) Rapidly progressive crescentic glomerulonephritis. Kidney Int 63(3):1164–1177CrossRefPubMed
18.
Zurück zum Zitat Haubitz M, Schellong S, Göbel U, Schurek HJ, Schaumann D, Koch KM, Brunkhorst R (1998) Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 41(10):1835–1844CrossRefPubMed Haubitz M, Schellong S, Göbel U, Schurek HJ, Schaumann D, Koch KM, Brunkhorst R (1998) Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 41(10):1835–1844CrossRefPubMed
19.
Zurück zum Zitat Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, Lesavre P, Jacquot C, Bindi P, Bielefeld P, Desson JF, Détrée F, Dubois A, Hachulla E, Hoen B, Jacomy D, Seigneuric C, Lauque D, Stern M, Longy-Boursier M (1997) A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum 40(12):2187–2198CrossRefPubMed Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, Lesavre P, Jacquot C, Bindi P, Bielefeld P, Desson JF, Détrée F, Dubois A, Hachulla E, Hoen B, Jacomy D, Seigneuric C, Lauque D, Stern M, Longy-Boursier M (1997) A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum 40(12):2187–2198CrossRefPubMed
20.
Zurück zum Zitat Li ZY, Gou SJ, Chen M, Zhao MH (2013) Predictors for outcomes in patients with severe ANCA-associated glomerulonephritis who were dialysis-dependent at presentation: a study of 89 cases in a single Chinese center. Semin Arthritis Rheum 42(5):515–521CrossRefPubMed Li ZY, Gou SJ, Chen M, Zhao MH (2013) Predictors for outcomes in patients with severe ANCA-associated glomerulonephritis who were dialysis-dependent at presentation: a study of 89 cases in a single Chinese center. Semin Arthritis Rheum 42(5):515–521CrossRefPubMed
21.
Zurück zum Zitat Lee T, Gasim A, Derebail VK, Chung Y, McGregor JG, Lionaki S, Poulton CJ, Hogan SL, Jennette JC, Falk RJ, Nachman PH (2014) Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. Clin J Am Soc Nephrol 9(5):905–913CrossRefPubMedPubMedCentral Lee T, Gasim A, Derebail VK, Chung Y, McGregor JG, Lionaki S, Poulton CJ, Hogan SL, Jennette JC, Falk RJ, Nachman PH (2014) Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. Clin J Am Soc Nephrol 9(5):905–913CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat de Groot K, Adu D, Savage CO, EUVAS (European vasculitis study group) (2001) The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 16(10):2018–2027CrossRefPubMed de Groot K, Adu D, Savage CO, EUVAS (European vasculitis study group) (2001) The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 16(10):2018–2027CrossRefPubMed
23.
Zurück zum Zitat de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, Luqmani R, Pusey CD, Rasmussen N, Sinico RA, Tesar V, Vanhille P, Westman K, Savage CO, EUVAS (European Vasculitis Study Group) (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150(10):670–680CrossRefPubMed de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, Luqmani R, Pusey CD, Rasmussen N, Sinico RA, Tesar V, Vanhille P, Westman K, Savage CO, EUVAS (European Vasculitis Study Group) (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150(10):670–680CrossRefPubMed
24.
Zurück zum Zitat Haubitz M, Frei U, Rother U, Brunkhorst R, Koch KM (1991) Cydophosphamide pulse therapy in Wegener’s granulomatosis. Nephrol Dial Transplant 6(8):531–535CrossRefPubMed Haubitz M, Frei U, Rother U, Brunkhorst R, Koch KM (1991) Cydophosphamide pulse therapy in Wegener’s granulomatosis. Nephrol Dial Transplant 6(8):531–535CrossRefPubMed
25.
Zurück zum Zitat Koldingsnes W, Gran JT, Omdal R, Husby G (1998) Wegener’s granulomatosis: long-term follow-up of patients treated with pulse cyclophosphamide. Br J Rheumatol 37(6):659–664CrossRefPubMed Koldingsnes W, Gran JT, Omdal R, Husby G (1998) Wegener’s granulomatosis: long-term follow-up of patients treated with pulse cyclophosphamide. Br J Rheumatol 37(6):659–664CrossRefPubMed
26.
Zurück zum Zitat Lê Thi Huong D, Papo T, Piette JC, Wechsler B, Blétry O, Lamas G, Baumelou A, Le Hoang P, Pennaforte JL, Valcke JC, Godeau P (1996) Monthly intravenous pulse cyclophosphamide therapy in Wegener’s granulomatosis. Clin Exp Rheumatol 14(1):9–16PubMed Lê Thi Huong D, Papo T, Piette JC, Wechsler B, Blétry O, Lamas G, Baumelou A, Le Hoang P, Pennaforte JL, Valcke JC, Godeau P (1996) Monthly intravenous pulse cyclophosphamide therapy in Wegener’s granulomatosis. Clin Exp Rheumatol 14(1):9–16PubMed
27.
Zurück zum Zitat Martin-Suarez I, D’Cruz D, Mansoor M, Fernandes AP, Khamashta MA, Hughes GR (1997) Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 56(8):481–487CrossRefPubMedPubMedCentral Martin-Suarez I, D’Cruz D, Mansoor M, Fernandes AP, Khamashta MA, Hughes GR (1997) Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 56(8):481–487CrossRefPubMedPubMedCentral
Metadaten
Titel
Late restoration of renal function in patients with severe ANCA-associated glomerulonephritis who were dialysis-dependent at presentation
verfasst von
Tian-Tian Ma
Yi-Ran Liu
Min Chen
Ming-Hui Zhao
Publikationsdatum
20.04.2018
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 8/2018
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-018-4100-8

Weitere Artikel der Ausgabe 8/2018

Clinical Rheumatology 8/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.